cisplatin,pemetrexed,pembrolizumab,gemcitabine
merck
['key,note,62', 'keynote,671', 'lcsm,(-blcsm)', 'keynote-671', 'key,note,24']
#asco23 #lcsm - keynote-671 primary endpoint: efs &amp; os with a mfu of 25.2m
efs at 24m: 62.4% vs 40.6% (hr 0.58)
estimated 24m os rate: 80.9 vs 77.6%
pcr 18.1 vs 4.0% mpr 30.2 vs 11.0% the 
MD PhD, lung oncologist & researcher @IEOufficiale; @myESMO Communication Committee Chair; #LungCancer Molecular target-believer #LCSM